Ignyta Inc (RXDX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Ignyta Inc (RXDX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH403905D
  • |
  • Pages: 54
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Ignyta Inc (Ignyta), formerly NexDx Inc is a drug manufacturing company that discovers, develops and commercializes new drugs targeting activated genes in cancer cells for the treatment of cancer patients. The company develops products using integrated therapeutic (Rx) and companion diagnostic (Dx) technology platform. Its clinical pipeline includes selective tyrosine kinase inhibitor of the TrkA, TrkB, TrkC, ROS1 and ALK protein and a small molecule inhibitor of BRAF, EGFR and RET. Ignyta's other pipeline products comprise taladegib, a small molecule smoothened antagonist; RXDX-105, a small molecule multikinase inhibitor; and RXDX-106, a small molecule, pseudo-irreversible inhibitor of TYRO3, AXL and Mer. The company also develops trailblaze diagnostic programs. Ignytais headquartered in San Diego, California, the US.

Ignyta Inc (RXDX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents

List of Tables

List of Figures

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Ignyta Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Ignyta Inc, Medical Devices Deals, 2012 to YTD 2018

Ignyta Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Ignyta Inc, Pharmaceuticals & Healthcare, Deal Details

Asset Purchase

Ignyta Acquires Four Oncology R&D Assets from Cephalon

Venture Financing

NexDx Raises USD5.5 Million In Series B Financing

Partnerships

Ignyta and Institut Curie Enter into Partnership

Ignyta Enters into Research Agreement with Moffitt Cancer Center

Merger

Ignyta And Infinity Oil & Gas Merge In Reverse Merger Transaction

Licensing Agreements

Ignyta Amends Licensing Agreement with Eli Lilly

Ignyta Amends Licensing Agreement with Nerviano Medical Sciences for RXDX-103 and RXDX-104 Inhibitors

Ignyta Amends Licensing Agreement with Nerviano Medical Sciences

Equity Offering

Ignyta Prices Public Offering of Shares for USD160 Million

Ignyta Raises USD88.4 Million in Public Offering of Shares

Ignyta Raises USD57.5 Million in Public Offering of Shares

Ignyta Raises USD30 Million in Private Placement of Shares

Ignyta Raises USD75 Million in Public Offering of Shares

Ignyta Raises USD42 Million in Private Placement of Shares

Ignyta Completes Public Offering Of Shares For USD55.2 Million

Ignyta Completes Private Placement Of Shares For USD7.8 Million

Ignyta Completes Private Placement Of Shares For USD46.2 Million

Acquisition

Roche to Acquire Ignyta for USD1.7 Billion

Ignyta Acquires Actagene Oncology

Ignyta Inc-Key Competitors

Ignyta Inc-Key Employees

Ignyta Inc-Locations And Subsidiaries

Head Office

Recent Developments

Financial Announcements

Nov 07, 2017: Ignyta Announces Third Quarter 2017 Company Highlights and Financial Results

Aug 08, 2017: Ignyta Announces Second Quarter 2017 Company Highlights and Financial Results

May 01, 2017: Ignyta Announces First Quarter 2017 Company Highlights and Financial Results

Mar 14, 2017: Ignyta Announces Full Year 2016 Company Highlights and Financial Results

Clinical Trials

Mar 03, 2017: Angsana's RNA-based fusions cancer panel selected for Ignyta's STARTRK2 clinical trial in Asia-Pacific

Feb 09, 2017: Ignyta's Updated Phase 1 Data on Safety, Anti-Tumor Activity and CNS Activity of Entrectinib in Cancers with TRK, ROS1 or ALK Fusions Published in Cancer Discovery

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer

List of Figures

Ignyta Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Ignyta Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Ignyta Inc, Medical Devices Deals, 2012 to YTD 2018

List of Tables

Ignyta Inc, Pharmaceuticals & Healthcare, Key Facts, 2016

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Ignyta Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Ignyta Inc, Deals By Therapy Area, 2012 to YTD 2018

Ignyta Inc, Medical Devices Deals, 2012 to YTD 2018

Ignyta Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Ignyta Acquires Four Oncology R&D Assets from Cephalon

NexDx Raises USD5.5 Million In Series B Financing

Ignyta and Institut Curie Enter into Partnership

Ignyta Enters into Research Agreement with Moffitt Cancer Center

Ignyta And Infinity Oil & Gas Merge In Reverse Merger Transaction

Ignyta Amends Licensing Agreement with Eli Lilly

Ignyta Amends Licensing Agreement with Nerviano Medical Sciences for RXDX-103 and RXDX-104 Inhibitors

Ignyta Amends Licensing Agreement with Nerviano Medical Sciences

Ignyta Prices Public Offering of Shares for USD160 Million

Ignyta Raises USD88.4 Million in Public Offering of Shares

Ignyta Raises USD57.5 Million in Public Offering of Shares

Ignyta Raises USD30 Million in Private Placement of Shares

Ignyta Raises USD75 Million in Public Offering of Shares

Ignyta Raises USD42 Million in Private Placement of Shares

Ignyta Completes Public Offering Of Shares For USD55.2 Million

Ignyta Completes Private Placement Of Shares For USD7.8 Million

Ignyta Completes Private Placement Of Shares For USD46.2 Million

Roche to Acquire Ignyta for USD1.7 Billion

Ignyta Acquires Actagene Oncology

Ignyta Inc, Key Competitors

Ignyta Inc, Key Employees

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license

Single User License
USD 250 INR 16648
Site License
USD 500 INR 33295
Corporate User License
USD 750 INR 49943

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com